All In Biotech

Drug Trial Radar · NCT07268820

Heartburn, Gastroesophageal Reflux Disease

A Multicenter, Double-blind, Randomized, Investigator-initiated Trial to Evaluate the Degree of Symptom Relief of Zastaprazan and Esomeprazole in Patients With Erosive Reflux Disease With Night-time Heartburn Symptoms

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jul 7, 2025

Primary completion

May 29, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Incheon St.Mary's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).

Conditions

  • GERD

Interventions

  • ZastaprazanDrug

    Participants in this arm will receive zastaprazan. This group serves as the experimental treatment group exploratorily evaluating drug for GERD.

  • EsomeprazoleDrug

    Participants in this arm will receive esomeprazole. This group serves as the active comparator treatment group exploratorily evaluating drug for GERD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants without sleep disturbance related to nighttime heartburn during the last 7 daysTime frame: Week 2

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Korea University Ansan Hospital

    Ansan, South Korea · Recruiting

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Kyungpook National University Chilgok Hospital

    Chilgok, South Korea · Recruiting

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea · Recruiting

  • Chonnam National University Hospital

    Gwangju, South Korea · Recruiting

  • Catholic University of Korea, Incheon ST. Mary's Hospital

    Incheon, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Kyung Hee University Hospital

    Seoul, South Korea · Recruiting

  • Soonchunhyang University Hospital

    Seoul, South Korea · Recruiting

  • Pusan National University Yangsan Hospital

    Yangsan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.